Experience of Oral Testosterone Replacement Therapy in ùùPADAMûû Patients at Menûs Health Clinic, Sappasitthiprasong Fort Hospital, Ubonratchathani
Keywords:
Oral testosterone undecanoate replacement therapy, partial androgen deficiency in aging male, erectile dysfunctionAbstract
Purpose: To share experience of oral testosterone replacement therapy and evaluated its efficacy and safety in ùùpadamûû patients.
Materials and methods: A total of 20 ùùpadamûû patients were treated with oral testosterone undecanoate does between 80 to 160 mg in 3 months interval. Mean age, Comorbidity diseases, ùùPadamûû symptoms, Severity of ùùpadamûû, Severity of ED, Laboratory check up and Free testosterone level in blood were evaluated.
Results: Mean age of patients was 60 year-old. Comorbidity were hypertension 30%, hyperlipidemia 25% and diabetis mellitus 15%. ùùPadamûû symptoms were decrease sexual intercourse 15%, decrease erection 15%, decrease well-being 15% and weakness 10%. AMS score and IIEF score improved signifi- cantly difference (p<0.05). Laboratory check up pre-and post-treatment were not differed. Low free test- osterone level in blood was 67% improved with significantly difference (p<0.05).
Discussion: I found that after oral testosterone undecanoate replacement therapy abount 3 months interval, 50% of ùpadamû patients were improved.
Conclusion: Oral testosterone therapy was efficacy and safety.
References
Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15 3): 212-5.
Hong JH, Ahn TY. Oral testosterone replacement in Korean patients with PADAM. The Aging Male 2002; 5(1): 52-56.
Li JY, Zhuj C, Dou JT, et al. Effects of androgen supplement therapy on partial androgen deficiency in the aging male. Aging Male 2002; 5(1): 47-51.
Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improved the quality of life for men with testosterone deficiency. Aging Male 2003; 6(2): 86-93.
Ludwig G. Padam from the urologic viewpoint. Urologe A 2000; 39(5): 407-10.
